CCR7

(redirected from EVI1)
Also found in: Acronyms.

CCR7

A gene on chromosome 17q12-q21.2 that encodes a member of the beta chemokine receptor family, which is similar to G protein-coupled receptors. CCR7 is expressed in various lymphoid tissues and activates B and T lymphocytes. It controls migration of memory T cells to inflamed tissues and stimulates dendritic cell maturation.
Mentioned in ?
References in periodicals archive ?
High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities.
The categorization of the remaining two individuals into the poor prognosis group was based on increased levels of EVI1 expression.
These included a lower frequency of NPM1ABD variants in the South African group (9.4%) when compared to the global average (32.5%) and a higher frequency of increased EVI1 expression (18.9%) when compared to the global average (9%).
AMLprofiler detects high levels of EVI1 expression in AML patients, which is a poor prognostic marker.
AMLprofiler has an added benefit in terms of high specificity and sensitivity with gene expression markers as it is designed to detect low levels of BAALC expression and high levels of EVI1 expression.
de Best et al., "A standardized microarray assay for the independent gene expression markers in AML: EVI1 and BAALC," Experimental Hematology & Oncology, vol.
The binding of ZF2 with its consensus sequence is essential for EVI1's activation.29 Furthermore, ZF2 is essential for the transactivation of the c-fos promoter, which is a main mechanism of activator protein 1 (AP1).
In mice, EVI1 is expressed in normal embryonic and adult long-term hematopoietic stem cells.
EVI1 exists as a single gene, or as part of a larger complex named MECOM, which stands for MDS1/EVI1 complex.
The relationship between inv(3), t(3;3), or other 3q26 rearrangements, and overexpression of EVI1 is not linear or interchangeable, because although the incidence of inv(3)/ t(3;3) and other 3q26 rearrangements is 2.24% among 6515 AMLs studied, (6) the incidence of EVI1 overexpression in AML is much higher--approximately 7.8% to 15.4% based on different studies.
(2011) Evi1 represses PTEN expression and activates PI3K/ AKT/mTOR via interactions with polycomb proteins.
ABCC1 a-f BCL2 a-b BCL2L11 a-d CDNK2B a-b DOK1 a-b EVI1 a-b KITLG a-b MAP4K4 a-d MYB a-d NPM1 a-b PTK2B a-c RUNX1 a-d RUNX1T1 a-b SEPT6 a-d TCL1B a-b WT1 a-d ZBTB16 a-b ZNF198 a-c ZNFN1A1 a-g Table 1.